The tremendous progress in imaging techniques over the past few years has not resulted in an earlier diagnosis of pancreatic cancer (PC). The search for a noninvasive diagnostic tool, capable of early diagnosis, led to the development of a series of tumor markers. This article discusses the evaluation of the latest one--CA 242--and its comparison with established markers such as CA 19.9, CA 50, and carcinoembryonic antigen (CEA).
No special preparation is needed for CA 242. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing CA 242. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||0-20U/ml|